NCT05515185尚未招募早期 1 期
An Open, Single-arm Clinical Study of Autologous T Cells (CAR-T) Targeting B7-H3 Chimeric Antigen Receptor Gene in the Treatment of Patients With Advanced Gastrointestinal Tumors
The First People's Hospital of Lianyungang1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年9月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicity
研究概览
简要总结
This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.
详细描述
This is a single-center, single-arm, open-label study. This study is planned to enroll about 30 subjects with advanced solid tumors. Autologous CAR-T cells were then infused intravenously into subjects, in a dose-escalating 3+3 design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-70 and of both sexes;
- •Advanced solid tumor diagnosed by histology or pathology;
- •Relapse after receiving chemotherapy or targeted drugs or other second-line therapy;
- •B7H3 antigen was positive in tumor tissues by immunohistochemistry, and the antigen expression rate was more than 15%.
- •Patients had at least one evaluable tumor lesion according to RECIST 1.1 criteria that could be accurately measured at baseline;
- •The ECOG score is 0-2, and the expected survival time is more than 12 weeks;
- •Laboratory test results should at least meet the following requirements:
- •Left ventricular ejection fraction ≥40%; Creatinine ≤200 umol/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L; Hemoglobin ≥80g/L; Oxygen saturation of blood 91%; Total bilirubin ≤2×ULN; ALT and AST 2.5 x ULN or less; The criteria for abnormal ALT and AST due to disease (e.g., liver metastases or bile duct obstruction) or Gilbert syndrome can be relaxed to ≤5×ULN.
- •Having venous access for blood collection or single blood collection;
- •The patient voluntarily participated and signed the informed consent in person.
排除标准
- •pregnant or lactating women;
- •Chemotherapy or radiotherapy was used within 3 days before the blood collection period;
- •Patients who have used systemic steroids within 5 days before blood collection period (except those who have recently or currently used inhaled steroids);
- •Use drugs to stimulate bone marrow hematopoietic cell formation within 5 days before the blood collection period;
- •Those who have used any gene or cell therapy products;
- •History of epilepsy or other central nervous system diseases;
- •Active hepatitis B or C virus, defined as: hepatitis B surface antigen HBsAg or hepatitis B core antibody HBcAb positive subjects with peripheral blood HBV DNA titer above the detection limit; HCV antibody positive for hepatitis C and HCV RNA positive in peripheral blood; People infected with HIV and syphilis;
- •Other tumors in the past 5 years;
- •Patients with severe chest and ascites;
- •There was active or uncontrollable infection requiring systemic treatment within 14 days before enrollment;
- •Other antineoplastic treatments (other than pretreatment and chemotherapy) were administered within 2 weeks before study initiation;
- •The investigator assessed that the patient was unable or unwilling to comply with the protocol.
研究组 & 干预措施
KT095 CAR-T
Experimental
KT095 CAR-T injection Intravenous infusion
干预措施: KT095 CAR-T injection (Drug)
结局指标
主要结局
Dose-limiting toxicity
时间窗: Up to 2 years
DLT
Maximum tolerable dose
时间窗: Up to 2 years
MTD
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of CAR T-Cells in Relapsed/Refractory Hematologic MalignancyRelapsed/refractory LymphomaRelapsed/Refractory LeukemiaNCT06756321Affiliated Hospital of Nantong University9
Unknown
早期 1 期
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT04626752Hebei Senlang Biotechnology Inc., Ltd.50
终止
1 期
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALLAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia RecurrentAcute Lymphoblastic Leukemia Not Having Achieved RemissionAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic LeukemiaNCT04049383Medical College of Wisconsin5
Unknown
不适用
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsB Cell LymphomaB Cell LeukemiaMyelomaPancreatic CarcinomaAdenocarcinoma of Esophagogastric JunctionHepatocellular CarcinomaNCT03302403Kang YU18
Unknown
1 期
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaRefractory or Relapsed Multiple MyelomaNCT03716856First Affiliated Hospital of Zhejiang University11